Red Light Holland Corp. News Releases

Red Light Holland Announces Corporate Rebrand to Rhelion Life Sciences Corp

Fri, 17 Jul 2026 07:50:00 -0400

Rhelion Life Sciences reflects the Company's evolution into a sharpened focused, science-driven life sciences platform dedicated to psychedelic drug discovery, development, and innovationToronto, Ontario--(Newsfile Corp. - July 17, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") is pleased to announce that it will be changing its corporate name to Rhelion Life Sciences Corp ("Rhelion"), marking the beginning of an exciting new chapter for the...

Red Light Holland Announces New Filament Health PEX010 European Research Shipment

Thu, 16 Jul 2026 08:03:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 16, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived...

Red Light Holland Announces Filament Health's Largest-Ever Manufacturing Run of PEX010, the Standardized and Patented Natural Psilocybin Drug Candidate Trusted Across 80+ Studies Globally, Now Offering the Widest Standardized Dosing Range, from 0.5 mg to 25 mg

Wed, 08 Jul 2026 08:00:00 -0400

Filament Health has commenced the largest production run in its history of its standardized, patented PEX010 botanical psilocybin drug candidate, introducing a new 0.5 mg dose alongside its existing 1, 5 and 25 mg strengths to deliver the widest standardized dosing range available from any natural psilocybin drug candidate, every strength produced using the same proprietary extraction and stabilization methods.Toronto, Ontario--(Newsfile Corp. - July 8, 2026) - Red Light Holland Corp. (CSE:...

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Military Veterans PTSD Study at ARQ National Psychotrauma Centre

Tue, 07 Jul 2026 08:12:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived...

Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filament Health

Thu, 18 Jun 2026 09:01:00 -0400

Whole leaf coca extract under evaluation is Magdalena's drug candidate for post GLP-1 weight loss managementToronto, Ontario--(Newsfile Corp. - June 18, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade...

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in France

Mon, 08 Jun 2026 07:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - June 8, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived...

Red Light Holland Announces Filament Health's PEX010 Drug Candidate, the Standardized and Patented Natural Psilocybin Trusted Across 80+ Studies Globally, Selected by UCSF for Study Probing Preclinical Alzheimer's Markers

Thu, 04 Jun 2026 07:30:00 -0400

Filament Health will supply its standardized, patented PEX010 botanical psilocybin drug candidate, produced using proprietary extraction and stabilization methods to an independently sponsored UCSF trial examining brain activity, neuroinflammatory markers, and preclinical Alzheimer's disease pathology in healthy older adults.Toronto, Ontario--(Newsfile Corp. - June 4, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an...

Red Light Holland Expands New Zealand Partnership with Allu Therapeutics to Advance Access to Filament Health's GMP-Compliant PEX010 Botanical Psilocybin Drug Candidate

Mon, 25 May 2026 08:40:00 -0400

The expanded agreement adds Filament Health, a wholly owned subsidiary of Red Light Holland, as a supplying affiliate and introduces a GMP-compliant standardized microdose format of PEX010 supported by long-term stability and safety data.Toronto, Ontario--(Newsfile Corp. - May 25, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company"), is an Ontario-based organization advancing innovation and research within the legal...

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Advances PEX010 Clinical Footprint with New Canadian Academic Studies in Palliative Care, Bipolar II Depression, and Healthy Adult Mechanism Research

Thu, 14 May 2026 08:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - May 14, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development...

Red Light Holland Announces Shareholder Approval of Name Change and Announces Voting Results from 2026 Annual General and Special Meeting of Shareholders

Wed, 13 May 2026 09:12:00 -0400

Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light Holland" or the "Company") is pleased to announce that shareholders overwhelmingly approved the Company's proposed corporate name change at the Company's annual general and special meeting of shareholders ("Shareholders") held on Monday, May 11, 2026 at the Company's office in Toronto (the "Meeting").The special resolution approving the Company's proposed name change...